- Home
- MRAM vs PLX Comparison
MRAM vs PLX Comparison
Compare MRAM & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- PLX
- Stock Information
- Founded
- MRAM 2008
- PLX 1993
- Country
- MRAM United States
- PLX Israel
- Employees
- MRAM N/A
- PLX N/A
- Industry
- MRAM Semiconductors
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRAM Technology
- PLX Health Care
- Exchange
- MRAM Nasdaq
- PLX Nasdaq
- Market Cap
- MRAM 140.4M
- PLX 132.5M
- IPO Year
- MRAM 2016
- PLX 1998
- Fundamental
- Price
- MRAM $6.48
- PLX $1.76
- Analyst Decision
- MRAM Strong Buy
- PLX
- Analyst Count
- MRAM 2
- PLX 0
- Target Price
- MRAM $9.00
- PLX N/A
- AVG Volume (30 Days)
- MRAM 105.3K
- PLX 404.5K
- Earning Date
- MRAM 10-30-2024
- PLX 11-14-2024
- Dividend Yield
- MRAM N/A
- PLX N/A
- EPS Growth
- MRAM N/A
- PLX N/A
- EPS
- MRAM 0.07
- PLX N/A
- Revenue
- MRAM $53,865,000.00
- PLX $45,667,000.00
- Revenue This Year
- MRAM N/A
- PLX N/A
- Revenue Next Year
- MRAM $7.15
- PLX $88.94
- P/E Ratio
- MRAM $88.20
- PLX N/A
- Revenue Growth
- MRAM N/A
- PLX N/A
- 52 Week Low
- MRAM $4.89
- PLX $0.82
- 52 Week High
- MRAM $9.43
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- MRAM 49.65
- PLX 61.19
- Support Level
- MRAM $6.30
- PLX $1.57
- Resistance Level
- MRAM $6.67
- PLX $1.83
- Average True Range (ATR)
- MRAM 0.23
- PLX 0.07
- MACD
- MRAM 0.00
- PLX -0.02
- Stochastic Oscillator
- MRAM 30.02
- PLX 59.62
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.